 Silence Therapeutics PLC LON:SLN, NASDAQ:SLN said it has begun dosing patients with SLN360, a putative treatment for elevated Lipoprotein a, bad cholesterol associated with increased risk of heart disease. The APOLLO phase I clinical study is designed to assess safety, tolerability and way the drug interacts with the body. 